sureselectqxt target enrichment for the illumina platform

SSIEM 2016 Annual Symposium

Phenotypes vary considerably ranging from acute neonatal onset with a fatal outcome to asymptomatic adults Methods: Targeted next-generation sequencing (NGS) of genes linked to 3MCGuria (MCCC1 MCCC2 HLCS BTD and CA5A) using HaloPlex enrichment and a paired-end 2 150 bp sequencing on a MiSeq platform (Illumina)

Illumina RNA Prep with Enrichment

Illumina RNA Prep with Enrichment can be used with the Illumina Exome Panel which features a highly optimized probe set that delivers comprehensive coverage of coding RNA sequences The Illumina Exome Panel includes 425 000 probes each constructed against the NCBI37/hg19 reference genome covering 98% of the RefSeq exome

Next

The probe-capture custom design targeted the 14893-pbF7 gene in two parts: chr13:113759000-113761350 and chr13:113764600-113775100 accounting for a total of 12 850 base-pairs with a gap of 3250 bp DNA library generation was performed using the Custom SureSelectQXT Target Enrichment system (Agilent Santa Clara CA USA) on a MiSeq platform

Clinical utility of NGS diagnosis and disease

The SureSelectQXT NGS target enrichment kit (Agilent Technologies) was used for library preparation following the manufacturer's protocol Paired end sequencing (2150 bp) was performed using the NextSeq 500/550 High Output V 2 Kit and NextSeq sequencing platform (Illumina California USA)

The Mutational Landscape of Circulating Tumor Cells

Mishima et al perform genomic analysis of circulating tumor cells of patients with multiple myeloma and find that circulating tumor cells have similar clonal and sub-clonal structures with matched bone marrow clonal plasma cells This study defines a role for CTCs in

Clinical utility of NGS diagnosis and disease

The SureSelectQXT NGS target enrichment kit (Agilent Technologies) was used for library preparation following the manufacturer's protocol Paired end sequencing (2150 bp) was performed using the NextSeq 500/550 High Output V 2 Kit and NextSeq sequencing platform (Illumina California USA)

Exome sequencing explained: a practical guide to its

2015-5-26Capture kits are vulnerable to off-target enrichment particularly when enrichment probes share sequence similarity with non-coding sequences [ 20 50] Furthermore there is difficulty in uniquely mapping to regions with high sequence identity e g gene families or repeated domains and in calling genotypes at the end of short reads

SureSelectQXT Automated Target Enrichment for Illumina

2019-4-4Automated Target Enrichment for Illumina Multiplexed Sequencing Featuring Transposase-Based Library Prep Technology Automated using Agilent NGS Workstation Option B Protocol Version C0 November 2015 SureSelect platform manufactured with Agilent SurePrint Technology For Research Use Only Not for use in diagnostic procedures

Development and validation of an ultra

For the 8 single cell lines using the Illumina HiSeq X platform achieving an average of 13 330 (SD=3 995 ) total bases with 38 09% on-target (SD=4 78%) target regions were sequenced to 2148X (SD=537X) median coverage across targeted bases with 99 05% (SD=0 28%) of targeted bases covered by at least 200 reads The 2453 SNV and 172

SureSelectQXT Automated Target Enrichment for Illumina

2019-4-4Target Enrichment for Illumina Sequencing (NGS Bravo Option A) 7 Content 1 Before You Begin 9 Procedural Notes 10 Safety Notes 11 Required Reagents 12 Optional Reagents 14 Required Equipment 15 2 Using the Agilent NGS Bravo Option A for SureSelect QXT Target Enrichment 17 About the Agilent NGS Bravo Option A 18 About the Bravo Platform 18

Abstracts from the 50th European Society of Human

However etiology of large proportion (71%) of infertile men still remained unknown Therefore we have performed exome sequencing to identify novel autosomal genetic causes of male infertility Materials and methods: Exome sequencing was performed in 44 idiopathic infertile men using Illumina Hiseq2000 platform with 100X coverage

Development and validation of an ultra

For the 8 single cell lines using the Illumina HiSeq X platform achieving an average of 13 330 (SD=3 995 ) total bases with 38 09% on-target (SD=4 78%) target regions were sequenced to 2148X (SD=537X) median coverage across targeted bases with 99 05% (SD=0 28%) of targeted bases covered by at least 200 reads The 2453 SNV and 172

Next

The probe-capture custom design targeted the 14893-pbF7 gene in two parts: chr13:113759000-113761350 and chr13:113764600-113775100 accounting for a total of 12 850 base-pairs with a gap of 3250 bp DNA library generation was performed using the Custom SureSelectQXT Target Enrichment system (Agilent Santa Clara CA USA) on a MiSeq platform

SureSelectQXT Target Enrichment for the Illumina Platform

2020-8-5SureSelectQXT Target Enrichment for Illumina Multiplexed Sequencing 3 Safety Notices CAUTION A CAUTION notice denotes a hazard It calls attention to an operating procedure practice or the like that if not correctly performed or adhered to could

NGS Services – NIMGenetics

NGS Services NIMGenetics team of professionals has extensive experience with NGS in both research and clinical spheres We offer a complete sequencing service with the highest quality standards that is adapted to meet the needs of researchers both in the processing of the sample in the performance required for each study and in

Evidence for a relatively high proportion of DM2

2018-11-1The Agilent SureSelectQXT Target Enrichment kit was used to generate the libraries and sequencing performed on MiSeq Illumina platform The CLCN1 gene variants identified in the patient were evidenced by Sanger sequencing also in her affected father and healthy mother Statistical analysis was performed using Statistica v 6 1 3 Results 3 1

Datasets

NimbleGen SeqCap EZ choice system was used as a target enrichment method (Roche Diagnostics) A DNA probe set complementary to the target region was designed by NimbleDesign The libraries were sequenced on the Illumina MiSeq platform with 2150-bp paired-end module (Illumina) Fastq files for 48 Japanese patients with endometriosis are deposited

GENE KNOCKOUT METHOD

2018-1-251 A method for producing a cell in which a target gene is knocked out the method comprising the step of: introducing a CRISPR-Cas system into a cell having one or more kinds of target genes the CRISPR-Cas system being able to produce (i) three or more kinds of guide RNAs for each of the one or more kinds of target genes and (ii) a Cas protein

SureSelect Automated Target Enrichment for Illumina

SureSelectQXT Automated Target Enrichment for Illumina Multiplexed Sequencing Featuring Transposase-Based Library Prep Technology Automated using Agilent NGS Bravo Option A Protocol Version B0 November 2015 SureSelect platform manufactured with Agilent SurePrint Technology For Research Use Only

[Full text] A comparison of QuantStudioTM 3D Digital

Plasma ctDNA was sequenced using paired-end strategy on an Illumina HiSeq platform (Illumina San Diego CA USA) as previously published 36 A KAPA Hyper Prep kit (Kapa Biosystems Inc MA USA) was used to construct the library Then the prepped libraries were hybridized with SureSelectQXT Target Enrichment System (Agilent Technologies) to

C11orf70 Mutations Disrupting the Intraflagellar

Primary ciliary dyskinesia (PCD) is a genetically and phenotypically heterogeneous disorder characterized by destructive respiratory disease and laterality abnormalities due to randomized left-right body asymmetry PCD is mostly caused by mutations affecting the core axoneme structure of motile cilia that is essential for movement Genes that cause PCD when mutated include a group that encode

Targeting a Single Alternative Polyadenylation Site

Prostate cancer is the second leading cause of male cancer deaths due to disease progression to castration-resistant prostate cancer (CRPC) Androgen receptor (AR) splice variants including AR-V7 function as constitutively active transcription factors in CRPC cells thereby promoting resistance to AR-targeted therapies To date there are no AR variant–specific treatments for CRPC

C11orf70 Mutations Disrupting the Intraflagellar

2018-5-1Library preparation was done using the SureSelectQXT Target Enrichment Kit (Agilent Technologies) Paired end sequencing (2 75 cycles) was performed using the NextSeq 500/550 High Output v2 kit and NextSeq platform (Illumina) A multiplex of 48 samples from affected individuals with PCD were sequenced per flow cell in each run using

SureSelect QXT Automated Target Enrichment for

SureSelectQXT Automated Target Enrichment for Illumina Multiplexed Sequencing Featuring Transposase-Based Library Prep Technology Automated using Agilent NGS Workstation Option B Protocol Version C0 November 2015 SureSelect platform manufactured with Agilent SurePrint Technology For Research Use Only Not for use in diagnostic procedures

The Mutational Landscape of Circulating Tumor Cells

2017-10-5we used the SureSelectQXT Target Enrichment kit (Agilent) All sequencing was performed on the Illumina HiSeq 2000 platform (Illumina) at the New York Genome Center or at the Broad Institute A detailed description of data processing is provided in the Supplemental Experimental Procedures